Welcome to BIOMED
BIOMED™ is a biotechnology company that is democratizing Healthcare, closing the “health gap,” and making Healthcare accessible to everyone regardless of gender, race or ethnicity, sexual identity, age, disability, socioeconomic status, and geographic location. We’re offering personalized and precision medicine with precise dosage, duration, release profiles, and combination of multiple drugs for any unique profile utilizing various technologies, including 3D bioprinting, Big Data, DNA, and A.I. and machine learning to enable predictive modeling that will improve patients’ health outcomes, enabling a significant leap forward in precision medicine.
The complexity and rise of data in healthcare means that artificial intelligence (AI) & Machine Learning will increasingly be applied to our health. One of BIOMED's key application categories involves diagnosis and treatment recommendations, patient engagement and adherence, and future applications in administrative activities.
Our research spans activities in contemporary chemical biology and drug discovery and blends the principles and experimental techniques of chemistry and biology with computational science.
This federal initiative aims to use today’s 3D printing technologies to improve supply chain resilience for American manufacturers. By accelerating the adoption of additive manufacturing (AM) across small and medium-sized companies, each of these AM-powered manufacturers will, in turn, contribute to building resilient supply chains for the U.S.-based domestic manufacturing ecosystem while also using 3D printing to improve their industrial competitiveness.
Partner with Us
Send your request and let one of our experts care about it.
Meet Our Specialists
Let us introduce our entire team of experts who make the success of our business.
I’ve been an advisor to the BIOMED team for several years, and I’m excited about the research of 3D tissue bioprinting operational model, specifically in the regulation of pulmonary epithelial cell differentiation.
Here is a short list of our most promising technologies. Innovation and commercialization of our technologies is the most important aspect of our commitment to our patients.
About 90 percent of potential new drugs fail in clinical trials because they are...
Cannabis and Cannabidiol Research Expansion Act 2022, The bipartisan legislation rolled back federal restrictions...
In his 2015 State of the Union address, President Obama announced that he launched...
The complexity and rise of data in healthcare means that artificial intelligence (AI) &...
Read here all our recent press releases, news, blogs, tips, reports, and everything related to Biomed and the biotechnology field
Today, Los Angeles, February 10, 2023 /PRNewswire/ — BIOMED, the leading next-generation healthcare platform, was chosen as one of the top ten finalists for the MedTech Color 2023 Pitch...Continue Reading
According to the World Health Organization, endometriosis is an often painful disorder that affects approximately 10% of women worldwide. Endometriosis grows endometrial-like tissue (uterine lining cells) in locations outside the uterus, including ovaries,...Continue Reading
Cannabis legalization has been an enormous success with a significant economic impact. The new report from this Federal Reserve Bank district shows how cannabis-related businesses create jobs and generate...Continue Reading
The legalization of cannabis has had a significant effect on pharmaceutical companies. A new study research project titled “U.S. Cannabis Laws Projected to Cost Generic, and Brand Pharmaceutical Firms Billions” used CRSP...Continue Reading
Nowadays almost every single person cares about aesthetic, their need to be accepted make them search for new and revolutionary treatments, we have seen an explosion of alternatives, it...Continue Reading